Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$103.68 USD
+0.23 (0.22%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $103.67 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 401 - 420 ( 528 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Stable - improved growth prospects and increasing Emerging Markets mix augur well
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Management raises mid-point of CY14 EPS guidance range - expects strong double-digit EPS growth for CY14 and ahead...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Management reiterates guidance of strong earnings growth of 10%, going forward, with performance in CY14 expected to be back-end loaded towards H2CY14....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Management guides for strong earnings growth of 10%, going forward, with performance in CY14
Provider: FIRST GLOBAL
Analyst: THOMAS K